The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy | Zendy

Jason R. Andrews | Zendy; Stephen D Lawn | Zendy; Corina Rusu | Zendy; Robin Wood | Zendy; Farzad Noubary | Zendy; Melissa A. Bender | Zendy; C. Robert Horsburgh | Zendy; Elena Losina | Zendy; Kenneth A. Freedberg | Zendy; Rochelle P. Walensky | Zendy

Open Access

The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy

Author(s) -

Jason R. Andrews,

Stephen D Lawn,

Corina Rusu,

Robin Wood,

Farzad Noubary,

Melissa A. Bender,

C. Robert Horsburgh,

Elena Losina,

Kenneth A. Freedberg,

Rochelle P. Walensky

Publication year - 2012

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e3283522d47

Subject(s) - medicine , tuberculosis , sputum , antiretroviral therapy , cost effectiveness , human immunodeficiency virus (hiv) , viral load , immunology , pathology , risk analysis (engineering)

In settings with high tuberculosis (TB) prevalence, 15-30% of HIV-infected individuals initiating antiretroviral therapy (ART) have undiagnosed TB. Such patients are usually screened by symptoms and sputum smear, which have poor sensitivity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog